Oxidation Injury in Patients Receiving HMG-CoA Reductase Inhibitors: Occurrence in Patients Without Enzyme Elevation or Myopathy

Author： Sinzinger H.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.25, Iss.12, 2002-01, pp. : 877-883

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HMG-CoA reductase inhibitors: Myopathy in patients with genetic mutations: 4 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1199, 2008-01 ,pp. : 27-27

Adis International

Access to resources Recommend Favorite

Prevalence of Potentially Severe Drug-Drug Interactions in Ambulatory Patients with Dyslipidaemia Receiving HMG-CoA Reductase Inhibitor Therapy

By Bravo Alexandra E. Rätz  

Drug Safety, Vol. 28, Iss. 3, 2005-01 ,pp. : 263-275

Adis International

Access to resources Recommend Favorite

HMG-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction

By Riahi S.   Hagstrup Christensen J.   Toft E.   Aarup Skou H.   Berg Schmidt E.  

Pharmacological Research, Vol. 45, Iss. 6, 2002-06 ,pp. : 479-483

Academic Press

Access to resources Recommend Favorite

The Effects of HMG-CoA Reductase Inhibitors on Endothelial Function

By Tesfamariam Belay  

American Journal of Cardiovascular Drugs, Vol. 6, Iss. 2, 2006-01 ,pp. : 115-120

Adis International

Access to resources Recommend Favorite

HMG-CoA Reductase Inhibitors in the Prevention of Stroke

By van Mil A.H.M.  

Drugs, Vol. 59, Iss. 1, 2000-01 ,pp. : 1-6

Adis International

Access to resources Recommend Favorite